BioNxt Receives Milestone EPO Decision to Grant European Patent for Sublingual Cladribine Drug Delivery Technology for Multiple Sclerosis

Core Viewpoint - BioNxt Solutions Inc. has received a Decision to Grant a European Patent for its proprietary sublingual cladribine oral thin film drug delivery technology, indicating a significant advancement in its product offerings and potential market position [1] Company Summary - BioNxt Solutions Inc. is a bioscience innovator focused on advanced drug delivery systems [1] - The company is publicly traded on multiple exchanges, including CSE, OTCQB, and FSE [1] Patent Information - The European Patent Office has granted European Patent No. 4539857 for BioNxt's sublingual cladribine oral thin film technology, which is a proprietary drug delivery method [1]